Analyst Report: LDOS

1. EXECUTIVE SUMMARY

On August 04, 2026, shares of Leidos Holdings, Inc. (NYSE: LDOS) surged 10.01% to close at $118.72 (touching intraday highs of $122.50) following a decisive Q2 2026 earnings beat, record quarterly free cash flow generation, and an upward revision to full-year 2026 financial guidance. Heading into the print, LDOS had been severely depressed—down nearly 35% to 40% YTD due to sector-wide government procurement friction and specific headwinds around Veterans Affairs (VA) incentive payment suspensions. However, a blowout performance in the core Defense segment—highlighted by a 2.2x book-to-bill ratio and high single-digit revenue expansion—demonstrated that the company's "NorthStar 2030" strategy is successfully accelerating revenue conversion. This move represents a sharp fundamental re-rating from trough single-digit P/E multiples, signaling that institutional capital is rotating back into high-cash-flow defense technology primes.

2. THE CATALYST (CRITICAL)

Specific Event Details

The primary catalyst for the 10.01% single-day stock surge was the release of Leidos Holdings, Inc.’s Q2 2026 financial results prior to the market open on August 04, 2026 (6:00 AM ET), accompanied by an executive conference call at 8:00 AM ET.

Key Financial Beat Metrics (Q2 2026)

Non-GAAP Diluted EPS: $3.26, surpassing the Wall Street consensus estimate of $2.90–$2.91 by $0.35 per share (a ~12% surprise).
Revenue: $4.558 Billion, representing a 7.2% YoY increase (4.0% organic growth) and topping analyst consensus estimates of $4.44 Billion by $118 Million–$160 Million.
Adjusted EBITDA: $631 Million (13.8% margin), beating the consensus expectation of $594.6 Million.
Cash Flow & Liquidity: Delivered record quarterly Operating Cash Flow of $793 Million and Non-GAAP Free Cash Flow (FCF) of $761 Million.
Bookings Momentum: Net contract awards totaled $5.0 Billion (overall 1.1x book-to-bill), propelled by a massive 2.2x book-to-bill ratio in the Defense segment.

+-----------------------------------------------------------------------+
|                       Q2 2026 SUMMARY VS ESTIMATES                   |
+-------------------+-----------------+-----------------+---------------+
| Metric            | Actual (Q2 '26) | Consensus Est.  | Variance      |
+-------------------+-----------------+-----------------+---------------+
| Revenue           | $4.558 Billion  | $4.440 Billion  | +$118M (+2.7%)|
| Non-GAAP EPS      | $3.26           | $2.91           | +$0.35 (+12%) |
| Adj. EBITDA       | $631 Million    | $594.6 Million  | +$36.4M (+6%) |
| Free Cash Flow    | $761 Million    | ~$400 Million   | +$361M (+90%) |
+-------------------+-----------------+-----------------+---------------+

Fiscal Year 2026 Guidance Upgrades

Management officially raised full-year guidance across revenue, EPS midpoints, and free cash flow generation:

Full-Year Revenue: Lifted midpoint by $100 Million to a new range of $18.20 Billion to $18.40 Billion.
Non-GAAP Diluted EPS: Guidance enhanced to $12.20 – $12.50.
Capital Allocation: Reduced 2026 Capex guidance to ~$250 Million, effectively boosting implied FY2026 Free Cash Flow guidance by $150 Million.
Capital Return: Re-confirmed ongoing execution of a newly authorized 20-million-share buyback program and declared a quarterly cash dividend of $0.43/share.

Cumulative Pre-Earnings Contract Momentum

The Q2 report was further reinforced by high-profile defense and space contract wins announced immediately preceding the earnings call:

Sierra Space Sensor Payload Contract (Aug 03, 2026): Selected to provide infrared sensing payloads and onboard signal processing for 18 missile defense satellites supporting the SDA proliferated LEO architecture ("Golden Dome for America").
Office of Naval Intelligence (ONI) Modernization (Aug 03, 2026): Awarded a contract worth up to $64.8 Million for worldwide secure naval intelligence systems modernization.
Low-Cost Containerized Munitions (LCCM) Framework (Aug 04, 2026): Signed an overarching framework agreement exceeding $1.0 Billion to deliver 3,000 containerized munitions by 2030.

3. COMPANY PROFILE

Core Business Model

Leidos Holdings, Inc. (NYSE: LDOS) is a global technology, engineering, and science solutions leader primarily serving government agencies and critical infrastructure operators. Headquartered in Reston, Virginia, with approximately 47,000–50,000 employees worldwide, the firm operates through four specialized segments:

Defense Systems: Digital modernization, C4ISR systems, kinetic & non-kinetic weapons systems integration, and maritime/space platform electronics.
National Security & Digital: Mission software, cyber operations, logistics intelligence, and decision analytics for the DoD and U.S. Intelligence Community.
Health & Civil: Public health IT, care management, medical disability exams for the Department of Veterans Affairs (VA), civil aviation (FAA), and infrastructure modernization.
Commercial & International: Power grid engineering, utility planning, energy resilience, and security screening technologies.

Key Corporate & Valuation Snapshot (As of August 04, 2026 Close)

Official Company Name: Leidos Holdings, Inc.
NYSE Ticker: LDOS
Market Capitalization: ~$14.93 Billion
Sector: Technology / Information Technology Services (Defense Prime)
Key Competitors: CACI International Inc (CACI), Science Applications International Corp (SAIC), Booz Allen Hamilton Holding Corp (BAH), General Dynamics (GD), L3Harris Technologies (LHX).
52-Week Range: $98.86 – $205.77
YTD Performance Context: Down ~34% to 37% YTD prior to the August 04 print, recovering to -27% YTD following the move.
Trailing / Forward P/E: ~10.8x TTM EPS; ~9.6x 2026 Guidance EPS (representing an extreme discount relative to historical defense tech multiples of 14x–18x).

4. DEEP DIVE ANALYSIS

Justification of Move: Fundamental Re-Rating or Overreaction?

This 10.01% rally is fully justified by fundamentals and represents an initial valuation correction rather than a speculative overreaction.

Prior to the Q2 earnings release, institutional sentiment around LDOS was excessively bearish. The market had aggressively priced in structural top-line deterioration following announcements that the Department of Veterans Affairs (VA) suspended vendor incentive payments in its Medical Disability Examination business. Analysts had slashed price targets across Wall Street (e.g., JPMorgan down to $160 from $210; Goldman Sachs to $152 from $171).

The Q2 2026 print invalidated the worst-case bear thesis:

Portfolio Diversification Absorbed Health Friction: While the Health segment slowed due to the VA pause, the Defense segment expanded rapidly with a 2.2x book-to-bill ratio, while Homeland Security revenue expanded 32% YoY.
Unprecedented Cash Generation: Generating $761 Million in quarterly free cash flow (on a ~$14.9B market cap) yields an annualized single-quarter FCF yield above 12–13%, giving management immense headroom for share buybacks at trough multiples.

       LEIDOS (LDOS) VALUATION COMPARISON (As of Aug 04, 2026)
+------------------------+------------------+-------------------+
| Metric                 | Leidos (LDOS)    | Peer Group Avg    |
+------------------------+------------------+-------------------+
| P/E (FY2026 Guidance)  | 9.6x             | 16.5x             |
| EV/EBITDA (Forward)    | 8.2x             | 13.1x             |
| Book-to-Bill Ratio     | 1.1x (Defense 2.2x)| 1.05x            |
| FCF Yield (2026 Est)   | ~11.5%           | ~5.5%             |
+------------------------+------------------+-------------------+

Peer & Sector Context

Defense IT peers (such as CACI and SAIC) have traded at modest multiples, but LDOS experienced disproportionate sell-offs early in 2026. With global geopolitical tensions driving increased Pentagon spending toward modern sensor suites, uncrewed platforms, and tactical AI cloud systems, Leidos demonstrated that legacy IT primes can capture high-margin mission integration contracts (e.g., CoreWeave secure AI cloud partnership, Parcata cybersecurity platform, Sierra Space infrared sensors).

Bull Case vs. Bear Case

Bull Case

Strong Pipeline Execution: A $12 Billion defense-tech pipeline over the next 12 months and $23 Billion in total submitted proposals position LDOS for sustained multi-year backlog growth.
Margin Expansion via High-Tech Integration: Pivoting from low-margin staffing toward outcome-based fixed-price software integration (NorthStar 2030 strategy) lifts EBITDA margins toward 14%.
Capital Allocation Upside: Lowering Capex to ~$250M while generating ~$1.5B+ in annual FCF enables aggressive share count reduction via the newly active 20-million-share buyback authorization.

Bear Case

VA Disability Examination Recompete Risk: Draft RFPs for the massive VA medical disability examination contract are expected imminently; loss of share or margin compression during recompete remains a medium-term headwind.
U.S. Budget / Continuing Resolution (CR) Delays: Any prolonged federal government budget impasse could delay award conversions from the $23B submission pipeline.

5. TECHNICAL SNAPSHOT

Technical Profile (Post-Earnings Close)

Closing Price: $118.72 (+$10.81 / +10.01%)
50-Day Moving Average (50-DMA): ~$113.23 (Decisively breached to the upside)
200-Day Moving Average (200-DMA): ~$145.90 (Major long-term overhead resistance)
Relative Strength Index (RSI - 14 Day): Shifted from oversold territory (~34) to neutral-bullish (~58).

   $205.77  ------------------------------------------- (52-Week High - Nov 2025)
            |
   $145.90  ------------------------------------------- (200-Day Moving Average)
            |
   $122.50  =========================================== (Immediate Resistance / Intraday High)
   $118.72  * * * CURRENT PRICE * * *
   $113.23  ------------------------------------------- (50-Day Moving Average Support)
   $107.27  ------------------------------------------- (Prior Consolidation Pivot)
   $98.86   ------------------------------------------- (52-Week Low - June 2026)

Volume & Price Action Analysis

Volume Spike: Trading volume surged significantly above its 30-day average volume (~1.3 Million shares), indicating strong institutional participation and short-covering activity rather than retail-driven churn.
Chart Pattern: The stock executed a classic earnings gap-and-go from a double-bottom base established between $98.86 (June low) and $107.20 (July low). A close above the 50-DMA confirms a short-term trend reversal.

Key Technical Levels

Immediate Resistance: $122.50 (August 04 intraday peak), followed by $132.00 (gap fill target from May 2026 breakdown).
Primary Support: $113.20 - $114.00 (50-DMA convergence zone).
Major Floor: $107.00 (pre-earnings baseline) and $98.86 (52-week low).

6. RISK FACTORS

Health Segment Contraction & VA Policy Shifts: The VA's temporary suspension of vendor incentive payments creates drag on Health & Civil revenue; any further administrative delays in VA contract extensions could pressure segment profitability.
Government Procurement Timelines: Although defense book-to-bill reached 2.2x in Q2, administrative protests or delays in federal budget appropriations could stall contract revenue execution.
Fixed-Price Contract Execution Risk: Pivoting toward outcome-based fixed-price defense systems carries margin risk if supply chain inflation or technical integration roadblocks occur.
Macroeconomic / Fiscal Budget Dynamics: Extended continuing resolutions (CRs) by the U.S. Congress could pause initial spending on newly awarded programs like the $1B containerized munitions framework.

7. ACTIONABLE OUTLOOK

Short-Term (1–2 Weeks): Bullish / Consolidation

Target Price: $124.00 – $126.00
Outlook: Expect minor profit-taking and consolidation around the $116.00–$119.00 range as short sellers complete covering. Any pullback toward the 50-DMA (~$113.20) represents an attractive entry point for momentum and value-oriented buyers.

Medium-Term (1–3 Months): Bullish Re-Rating

Target Price: $135.00 – $142.00
Key Drivers: Wall Street analyst price target upward revisions following the beat-and-raise quarter; execution of share buybacks under the 20M share authorization; official RFP releases for defense and intelligence proposals ($23B pipeline).

Long-Term Thesis (12+ Months): Structurally Intact & Undervalued

Target Price: $160.00 – $170.00
Thesis: The long-term thesis has fundamentally strengthened. At sub-10x forward earnings, market pricing failed to reflect Leidos' transition into high-margin defense software, hypersonics tracking payloads, and autonomous systems. As defense technology spending accelerates globally and FCF conversion remains above 100%, LDOS offers superior risk-adjusted return potential with strong downside protection.

LDOS

Leidos Holdings, Inc.

Price history